Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAB4 + saccharomyces boulardii
- Development stage
- Unknown
- Lead developer
- Lab4 Probiotics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
LAB4 + saccharomyces boulardii is a multi-strain probiotic combination consisting of the LAB4 bacterial consortium and the probiotic yeast *Saccharomyces boulardii*. The LAB4 consortium is a proprietary blend of four strains: *Lactobacillus acidophilus* (CUL60), *Lactobacillus acidophilus* (CUL21), *Bifidobacterium animalis* subsp. *lactis* (CUL34), and *Bifidobacterium bifidum* (CUL20). This combination is designed to support gastrointestinal health by modulating the gut microbiota, enhancing intestinal barrier function, and providing competitive inhibition against enteric pathogens. It is primarily utilized for the prevention of antibiotic-associated diarrhea and traveler's diarrhea, as well as the management of symptoms associated with irritable bowel syndrome (IBS). The product was developed by Cultech and is marketed under the ProVen Probiotics brand.
- Brand names
- ProVen Probiotics Adult Acidophilus & Bifidus with Saccharomyces BoulardiiProVen Probiotics Travel Probiotic
- Other names
- LAB4 with Saccharomyces boulardiiLAB-4 with Saccharomyces boulardiiLAB 4 with Saccharomyces boulardiiLAB4 plus Saccharomyces boulardiiLAB-4 plus Saccharomyces boulardiiLAB 4 plus Saccharomyces boulardii
Beyond the preview
Go deeper on LAB4 + saccharomyces boulardii.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAB4 + saccharomyces boulardii.